JUL 31, 2018 05:45 PM PDT

Protein Regulation of DNA Replication in Cancer Cells - A New Early Target for Broad Therapeutics?

Researchers have been examining the loss of control over the DNA replication and cell proliferation process since it was connected to the development of cancer.  One of the most well-known and common traits of the disease in all types of cancer diagnoses is this this uncontrolled cellular replication and growth. 

In healthy cells, this process is carefully regulated and controlled through pathways and cellular checkpoints.  In a Nature Communications article published July 17, 2018, researchers identified a replication initiation determinant protein (RepID) that regulates replication through association of other proteins, drawing them directly to chromatin sites for replication initiation.  One of these proteins is a Culling-RING E3 ubiquitin ligase (CRL) which one of many CRLs.  CRL4 is recruited by RepID to chromatin in the very early stages of mitosis (cell cycle) prior to replication.  CRL4 acts to degrade CDT1, a protein that promotes replication at the appropriate time in the cell cycle.  Loss of CDT1 is the switch that tells a cell to only begin the DNA replication cycle once.  In addition to CRLs, a complex called SCF is also part of the cell cycle progression in mammals.  It, too, can facilitate degradation of chromatin proteins involved in regulation of mitosis and DNA replication later in the cell cycle (the S-phase).

In cases of RepID loss of expression or function, turning off that CDT1 switch is up to the SCF complex later in the cell cycle.  However, because the degradation was originated after DNA replication began, the cell re-replicated its DNA because there were higher levels of CDT1 associated with the chromatin.

Part of the SCF complex is a protein called SKP2.  This group of researchers treated the depleted RepID cancer cell cultures with a drug that inhibits SKP2, known as SZL-P1-41.  Their findings indicated that cells expressing intact RepID were not affected by the SKP2 inhibitor but cells with no RepID showed high sensitivity to SKP2 inhibition. The RepID knockout cells entered apoptosis and there were no surviving colonies in cell culture.  The researchers conclude that, “RepID expression levels might modulate the sensitivity of cancer cells to cullin-targeting drugs.”

Sources: Nature Communications, National Cancer Institute,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
OCT 18, 2019
Cancer
OCT 18, 2019
This Ovarian Cancer Drug Prolongs Life
Niraparib is a drug and a PARP inhibitor that targets cancer cells without harming others. PARP inhibitors keep PARP -- proteins that fix damaged DNA in ca...
OCT 18, 2019
Health & Medicine
OCT 18, 2019
Does Cuttlefish Ink Hold a Cure for Cancer?
Using nanoparticles to deliver cancer-fighting compounds directly into tumors has been a hot research topic for the past few years. According to Lisa Ayga...
OCT 18, 2019
Genetics & Genomics
OCT 18, 2019
Genetic Cause for Tumor Progression
Researchers from the University of Delaware (UDEL), Harvard Medical School (HMS) and University of California, Los Angeles (UCLA), have discovered a ribonu...
OCT 18, 2019
Drug Discovery & Development
OCT 18, 2019
Leukemia Drug Effective for Treating Childhood Brain Cancer
Scientists at the University of California-San Diego have found that a chronic myeloid leukemia drug was found to treat medulloblastoma in mouse models mor...
OCT 18, 2019
Cancer
OCT 18, 2019
Handheld device detects skin cancer
I can’t be the only one who has ever looked at a suspicious freckle and wondered, “Could this be skin cancer?” Of course, when 9,500 Amer...
OCT 18, 2019
Genetics & Genomics
OCT 18, 2019
A Cancer-Promoting Mutation is Found in 'Junk' DNA
A huge amount of our genome does not code for protein, but it can impact physiology in other ways....
Loading Comments...